GEP-NET
Oncology · 2017–2024
4decisions
1medicine
2carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lanreotide Changes to Community Access (CA) listings to allow initiation of treatment for acromegaly, functional carcinoid tumour, and non-functional… | Jul 2024 | Recommended with restriction | 3 individuals |
| lanreotide Treatment of acromegaly, functional carcinoid tumour, and gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally… | Nov 2022 | Recommended with restriction | input received NeuroEndocrine Cancer Australia |
| lanreotide Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET) in patients requiring continuing treatment of unresectable locally advanced or metastatic… | Mar 2019 | Recommended with restriction | none received |
| lanreotide Treatment of non-functional gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with unresectable locally advanced or metastatic disease, WHO… | Nov 2017 | Recommended | none received |
Who spoke
NeuroEndocrine Cancer Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.